Johnson & Johnson announced it has successfully completed its acquisition of Aragon Pharmaceuticals Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Development of compounds from Aragon’s androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development LLC.
“The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound,” said Peter Lebowitz, Global Therapeutic Area Head, Oncology. “It builds on our existing leadership position with Zytiga (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients.”
Date: August 19, 2013
Source: Johnson & Johnson
